Seaport Therapeutics Inc.

05/06/2026 | Press release | Distributed by Public on 05/06/2026 19:17

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
GAP Coinvestments CDA, L.P.
2. Date of Event Requiring Statement (Month/Day/Year)
05/04/2026
3. Issuer Name and Ticker or Trading Symbol
Seaport Therapeutics, Inc. [SPTX]
(Last) (First) (Middle)
C/O GENERAL ATLANTIC SERVICE CO., L.P., 55 EAST 52ND STREET, 33RD FLOOR
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
NEW YORK, NY 10055
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value $0.0001 per share ("Common Stock") 6,101,582 I See footnote(1)(2)(3)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
GAP Coinvestments CDA, L.P.
C/O GENERAL ATLANTIC SERVICE CO., L.P.
55 EAST 52ND STREET, 33RD FLOOR
NEW YORK, NY 10055
X X
General Atlantic Partners (Lux), SCSp
412F, ROUTE D'ESCH
LUXEMBOURG L-1471
X X
General Atlantic (Lux) S.a r.l.
412F, ROUTE D'ESCH
LUXEMBOURG L-1471
X X
General Atlantic GenPar (Lux) SCSp
412F, ROUTE D'ESCH
LUXEMBOURG L-1471
X X

Signatures

/s/ Michael Gosk 05/06/2026
**Signature of Reporting Person Date
/s/ Ingrid van der Hoorn 05/06/2026
**Signature of Reporting Person Date
/s/ Ingrid van der Hoorn 05/06/2026
**Signature of Reporting Person Date
/s/ Ingrid van der Hoorn 05/06/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Reflects 6,101,582 shares of Common Stock held by General Atlantic (SP), L.P., or General Atlantic SP, including 3,351,582 shares of Common Stock issuable upon conversion of Series B preferred stock. The limited partners that share beneficial ownership of the shares held by General Atlantic SP, or the GA Funds, are General Atlantic Partners 100, L.P., or GAP 100, General Atlantic Partners (Lux), SCSp, or GAP Lux, GAP Coinvestments III, LLC, or GAPCO III, GAP Coinvestments IV, LLC, or GAPCO IV, GAP Coinvestments V, LLC, or GAPCO V, and GAP Coinvestments CDA, L.P., or GAPCO CDA. The general partner of GAP 100 is General Atlantic GenPar, L.P., (Cont'd in FN2)
(2) (Cont'd from FN1) or GA GenPar. General Atlantic, L.P., or GA LP, which is controlled by the Partnership Committee of GASC MGP, LLC (the "Partnership Committee"), is the managing member of GAPCO III, GAPCO IV and GAPCO V, the general partner of GAPCO CDA and GA GenPar, and the sole member of General Atlantic (SPV) GP, LLC, or GA SPV. The general partner of General Atlantic SP is GA SPV. The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, or GA GenPar Lux, and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a r.l., or GA Lux. The sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., or GenPar Bermuda. GAP (Bermuda) L.P., or GAP Bermuda, which is ultimately controlled by the Partnership Committee, is the general partner of GenPar Bermuda. (Cont'd in FN3)
(3) (Cont'd from FN2) There are six members of the Partnership Committee. Each of the members of the Partnership Committee disclaims ownership of the shares except to the extent that he or she has a pecuniary interest therein.

Remarks:
GA LP, GAP Bermuda, GA Lux, GA GenPar Lux, GA SPV, and the GA Funds may be deemed to be members of a "group" for the purposes of the Securities Exchange Act of 1934. Each reporting person disclaims beneficial ownership of any securities deemed to be owned by the group that are not directly owned by the reporting person. This report shall not be deemed an admission that the reporting persons are a member of a group or the beneficial owner of any securities not directly owned by the reporting person. Each of the reporting persons is a director-by-deputization solely for purposes of Section 16 of the Exchange Act. // Form 2 of 2
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Seaport Therapeutics Inc. published this content on May 06, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 07, 2026 at 01:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]